![Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer]()
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate CancerHeath, Elisabeth; Heilbrun, Lance; Mannuel, Heather; Liu, Glenn; Lara, Primo; Monk, J. Paul; Flaig, Thomas; Zurita, Amado; Mack, Philip; Vaishampayan, Ulka; Stella, Philip; Smith, Daryn; Bolton, Susan; Hussain, Arif; Al‐Janadi, Anas; Silbiger, Daniel; Usman, Muhammad; Ivy, S. Percy · The Oncologist · 2019